Rafael Holdings reports Q4 net loss $0.19/share; full year loss $1.45/share; merger with Cyclo ongoing

Rafael Holdings, Inc.

2025-Q1 EPS reported -$0.37 revenue$128,000

Q4 net loss from continuing ops $4.5M ($0.19/diluted) vs gain $1.3M ($0.06) year ago.
Full year net loss $34.4M ($1.45/diluted) vs loss $8.4M ($0.36) prior year; includes $89.9M in-process R&D charge.
Cash and marketable securities $65.9M as of July 31, 2024.
Merger with Cyclo Therapeutics (CYTH) progressing; Phase 3 study fully enrolled, interim results mid-2025.
R&D expenses $4.2M for fiscal year, down from $6.3M due to winding down early-stage programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.